Intellia Therapeutics, Inc. NTLA
Intellia Therapeutics, Inc. ("we," "us," "our," "Intellia," or the "Company") is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.
For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles ("LNPs"), to develop novel, first-in-class product candidates. This includes the development of lonvoguran ziclumeran ("lonvo-z," also referred to as NTLA-2002) for the treatment of hereditary angioedema ("HAE") and nexiguran ziclumeran ("nex-z," also referred to as NTLA-2001) for the treatment of transthyretin ("ATTR") amyloidosis. These lead product candidates are the first in vivo genome editing product candidates into Phase 3 development. These systemically administered CRISPR-based candidates are designed to address diseases with high unmet need with a single intravenous ("IV") infusion that is administered in an outpatient setting. Lonvo-z and nex-z are currently in Phase 3 clinical development, and we are preparing for the planned commercial launch of lonvo-z in the first half of 2027.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M | $58.0M | $43.1M | $30.4M | $26.1M | $16.5M |
| Cost of revenue | — | — | — | — | $0 | $0 | $0 | $0 | — | — |
| Gross profit | — | — | — | — | $33.1M | $58.0M | $43.1M | $30.4M | — | — |
| R&D | $388.9M | $466.3M | $435.1M | $420.0M | $229.8M | $150.4M | $108.4M | $89.1M | $67.6M | $31.8M |
| SG&A | $119.8M | $125.8M | $116.5M | $90.3M | $71.1M | $44.2M | $41.1M | $32.2M | $28.0M | $16.8M |
| Total operating expenses | $508.7M | $592.1M | $551.6M | $510.3M | $300.9M | $194.6M | $149.5M | $121.3M | $95.7M | $48.6M |
| Operating income | -$441.0M | -$534.3M | -$515.3M | -$458.2M | -$267.9M | -$136.6M | -$106.4M | -$90.9M | -$69.6M | -$32.2M |
| Pre-tax income | -$412.7M | — | — | — | — | — | — | — | -$67.5M | -$31.6M |
| Income tax | $0 | — | — | — | — | — | — | — | — | $0 |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M | -$267.9M | -$134.2M | -$474.2M | -$85.3M | -$67.5M | -$31.6M |
| EPS, basic | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | — | — | — | — |
| EPS, diluted | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | -2.11 | -1.98 | -1.88 | -1.42 |
| Shares, diluted (wtd. avg.) | 108.4M | 98.8M | 88.8M | 77.0M | 70.9M | 56.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $155.5M | $189.2M | $226.7M | $523.5M | $123.4M | $160.0M | $57.2M | $58.9M | $340.7M | $273.1M |
| Short-term investments | $294.4M | $412.3M | $685.5M | $669.1M | $625.3M | $437.4M | $222.5M | $255.2M | — | — |
| Receivables | $9.5M | $8.5M | $36.5M | $3.8M | $2.0M | $2.1M | $4.6M | $7.5M | $10.5M | $6.5M |
| Total current assets | $527.7M | $639.9M | $998.3M | $1.22B | $769.3M | $616.5M | $289.5M | $325.0M | $354.8M | $281.3M |
| Property, plant and equipment | $17.7M | $27.4M | $32.8M | $27.9M | $21.0M | $15.9M | $18.0M | $17.1M | $15.3M | $10.6M |
| Total assets | $842.1M | $1.19B | $1.30B | $1.52B | $1.29B | $676.3M | $334.3M | $347.3M | $376.2M | $299.0M |
| Accounts payable | $20.3M | $14.6M | $7.5M | $5.2M | $9.7M | $10.5M | $3.9M | $2.7M | $2.2M | $4.7M |
| Total current liabilities | $103.9M | $110.9M | $115.2M | $126.6M | $125.8M | $64.3M | $35.6M | $40.6M | $31.4M | $30.7M |
| Total liabilities | $170.7M | $319.1M | $250.8M | $284.5M | — | — | — | — | — | — |
| Retained earnings | -$2.59B | -$2.18B | -$1.66B | -$1.18B | -$703.0M | -$435.1M | -$300.9M | -$201.0M | -$121.1M | -$53.6M |
| Total equity | $671.4M | $872.0M | $1.05B | $1.24B | $1.04B | $527.1M | $269.9M | $277.9M | $300.6M | $209.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$394.7M | -$348.9M | -$394.1M | -$333.3M | -$225.0M | -$49.9M | -$103.2M | -$61.3M | -$65.3M | $36.1M |
| Depreciation and amortisation | $9.8M | $10.3M | $9.0M | $7.6M | $6.9M | $6.3M | $5.6M | $4.5M | $3.0M | $1.1M |
| Stock-based compensation | $80.2M | $154.3M | $134.1M | $91.4M | $47.0M | $19.9M | $15.1M | $17.0M | $15.3M | $6.7M |
| Capital expenditure | $1.1M | $5.8M | $14.0M | $13.6M | $12.8M | $3.6M | $6.8M | $6.4M | $10.1M | $6.2M |
| Investing cash flow | $228.0M | $125.6M | -$31.3M | $160.3M | -$550.8M | -$214.5M | $25.2M | -$260.8M | -$10.1M | -$6.2M |
| Financing cash flow | $131.5M | $185.7M | $130.3M | $583.0M | $736.7M | $371.8M | $76.4M | $40.2M | $143.0M | $167.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197283.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Gross profit | — | — | $30.4M | $43.1M | $58.0M | $33.1M | — | — | — | — |
| Net income | -$31.6M | -$67.5M | -$85.3M | -$474.2M | -$134.2M | -$267.9M | -$474.2M | -$481.2M | -$519.0M | -$412.7M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.15B | 42.8x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.51B | 29.3x | 0.5% |
| NEOG | NEOGEN CORP | $2.66B | — | -2.7% |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | — | -78.0% |
| QDEL | QuidelOrtho Corp | $941.5M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $667.8M | — | — |
| MYGN | MYRIAD GENETICS INC | $556.7M | — | -1.6% |
| TKNO | Alpha Teknova, Inc. | $344.7M | — | 7.4% |